Biopharma deal activity in 2025 has surged to record levels, with $164 billion in transactions in the first seven months, reflecting robust mergers and financings despite a drought in IPOs. Year-to-date IPO funding has declined to the lowest since 2016, with most IPOs occurring outside the U.S., particularly in Asia. This mixed fundraising landscape underscores shifting investor strategies amid market volatility and regulatory challenges.